The Cooper Companies, Inc. research snapshot
COO AI stock analysis currently reads CooperCompanies as a durable medical device business with recurring contact lens demand, a global CooperVision franchise, improving CooperSurgical execution, and a management plan focused on margin repair, free cash flow, buybacks, and debt reduction. The setup is not a clean buy signal because GAAP earnings were pressured by a CooperSurgical fertility media recall litigation charge, Asia Pacific CooperVision revenue was soft in Q2 2026, and the stock still trades at about 61.53x TTM GAAP EPS despite a much lower forward non-GAAP multiple. The COO AI stock forecast therefore uses scenario ranges, not a precise price promise, and treats organic growth, recall settlements, CooperSurgical strategic review, tariffs, margins, cash conversion, and the 200-day moving average as the main variables.
Current price
$72.61
Market cap
$14.16 billion verified market cap
AI score
67 / 100
Rating
Quality medical device compounder with litigation and valuation sensitivity
Trend status
Recovering short-term, still below the 200-day moving average
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | CooperCompanies sells contact lenses through CooperVision and fertility, office, and surgical products through CooperSurgical. Demand is recurring and healthcare-linked, but product quality and regulatory execution matter. | High |
| Moat | Brand, practitioner relationships, fitting habits, product breadth, toric and multifocal know-how, scale manufacturing, and channel access support the moat. It is narrower in CooperSurgical because fertility and surgical markets remain more procedure and reputation sensitive. | Medium-high |
| Management | CEO Al White has emphasized product launches, reorganization savings, cash generation, share repurchases, debt reduction, and a strategic review of CooperSurgical. The current test is execution after the fertility media recall settlement. | Medium-high |
| Financial trend | FY2025 revenue was $4.092 billion, up 5%, and Q2 2026 revenue was $1.082 billion, up 8%. TTM net income is lower because Q2 included a litigation-related charge. | High |
| Valuation | At $72.61, COO screens near 61.53x TTM GAAP EPS, 1.72x book, 24.87x FCF per share, and about 15.34x forward earnings, so normalized EPS assumptions drive the valuation debate. | High |
| Technical trend | The stock is above the 50-day moving average near $64.39 but below the 200-day average near $72.82, with RSI near 66.97. That is a recovery test, not a confirmed long-term uptrend. | Medium |
| Risk level | Main risks are product recall liabilities, CooperSurgical reputation, strategic-review uncertainty, tariffs, currency, Asia Pacific weakness, debt, valuation compression, and contact lens competition. | Medium-high |
| AI confidence | Descriptive confidence is high because financial and market data are well sourced. Return confidence is lower because GAAP earnings, litigation cash timing, and strategic-review outcomes can change the range quickly. | High data confidence |
| Investment certainty | COO has a strong healthcare franchise, but the current price needs clean execution, stable recall resolution, and visible non-GAAP EPS to free cash flow conversion to become a high-certainty setup. | Medium |
COO AI stock forecast
The COO AI stock forecast is scenario-based because GAAP EPS is temporarily depressed by litigation while management guidance and analyst models focus on non-GAAP earnings. Using the $72.61 price reference, FY2026 non-GAAP EPS guidance midpoint near $4.62, and the audited three-year model, the mechanical range points to about $57.10 in a bear case, $90.60 in a base case, and $123.30 in a bullish case before any capital-return impact. StockAnalysis listed an $80.57 average analyst target, but this page treats that as sentiment context rather than a forecast promise.
$105 to $125 before capital-return impact
More likely if CooperVision sustains mid-single-digit organic growth, CooperSurgical stabilizes after recall settlements, tariffs are absorbed, non-GAAP margins stay near 27%, free cash flow moves toward the 2026 to 2028 objective, and the market applies a high-teens multiple to normalized EPS.
$78 to $95 before capital-return impact
More likely if revenue grows near guidance, non-GAAP EPS compounds around the high single digits, buybacks offset dilution, recall cash payments remain manageable, and valuation stays near a mid-teens normalized earnings multiple.
$55 to $65 before capital-return impact
More likely if litigation cash costs exceed expectations, CooperSurgical loses fertility momentum, Asia Pacific CooperVision weakness persists, tariffs pressure margins, or investors value COO on low-cycle GAAP earnings rather than normalized EPS.
COO AI technical analysis
COO AI technical analysis is mixed as of the July 8, 2026 data cutoff. StockAnalysis listed a July 6 close of $72.61, market cap near $14.16 billion, a 50-day moving average near $64.39, a 200-day moving average near $72.82, RSI near 66.97, and 20-day average volume near 3.78 million shares. That setup places COO above short-term trend support but still testing long-term resistance.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $72.61 | StockAnalysis listed the July 6, 2026 close at $72.61, with a July 7 pre-market reference near $72.69. |
| Immediate support | $71 to $72 | This area sits around the recent close and the 200-day test zone, where a failed hold would weaken the post-Q2 recovery. |
| Deeper support | $58 to $65 | This range brackets the 52-week low near $58.89 and the 50-day moving average near $64.39. |
| Near resistance | $72.80 to $74.50 | The 200-day moving average near $72.82 and recent intraday highs around $74 are the first levels bulls need to clear. |
| Upper resistance | $80 to $90 | This range overlaps the StockAnalysis average analyst target near $80.57 and the 52-week high near $89.83. |
| Moving averages | 50-day near $64.39, 200-day near $72.82 | A hold above the 50-day average shows short-term recovery, while a sustained close above the 200-day average would improve the long-term trend read. |
| Momentum | RSI near 66.97 | Momentum is constructive but close enough to the upper range that failed breakouts can reverse quickly. |
| Volume | 20-day average near 3.78 million shares | Volume confirmation matters because COO has recently reacted sharply to earnings, analyst target cuts, and litigation updates. |
| Volatility | Watch August 26, 2026 estimated earnings | The next earnings update, CooperSurgical review headlines, recall cash timing, tariff commentary, and FY2026 guidance changes are likely volatility drivers. |
| Invalidation | Close below $71, then below $58.89 | A sustained break below the recent support area would weaken the recovery setup. A break below the 52-week low would reset the larger range lower. |
COO AI trading strategy
The COO AI trading strategy below is a rules-based research framework, not personal advice. It connects chart levels with contact lens demand, CooperSurgical execution, recall liabilities, margin guidance, free cash flow, debt, buybacks, tariffs, and analyst estimate revisions.
Watch for COO to close and hold above the $72.80 to $74.50 resistance zone with stable guidance, clean recall commentary, and improving volume. A move through that zone would suggest the market is valuing normalized EPS more than depressed GAAP EPS.
A failed breakout followed by a close below $71 should reduce trend confidence, especially if management signals recall cash pressure, weaker CooperSurgical demand, or margin pressure from tariffs.
If COO retests the $58 to $65 area without a new product-quality issue, compare the lower price with free cash flow per share, debt reduction, buyback capacity, CooperVision organic growth, and the strategic value of CooperSurgical.
Do not treat every pullback as attractive if legal liabilities are expanding, Asia Pacific weakness is spreading, or management lowers the 2026 to 2028 free cash flow objective.
Track CooperVision organic growth, toric and multifocal demand, MyDay MiSight traction, CooperSurgical fertility growth, SG&A litigation charges, cash conversion, net debt, interest expense, buybacks, and analyst EPS revisions.
Position sizing should reflect that COO is a quality healthcare business with event risk, not a risk-free compounding vehicle or a guaranteed recovery trade.
Investment research summary
Customers pay CooperCompanies because vision correction, eye-care practitioner fitting, fertility workflows, and surgical products solve recurring healthcare needs. CooperVision is the economic core, while CooperSurgical adds procedure exposure and higher recent execution risk.
The moat comes from contact lens brands, practitioner relationships, fitting behavior, specialty lenses, manufacturing scale, global distribution, and product development. It is meaningful but not unbreakable because competitors can pressure price, innovation, and channel attention.
The thesis fails if recall liabilities or product quality issues damage trust, CooperSurgical remains a drag, tariffs and currency compress margins, CooperVision loses share in premium lenses, or the market refuses to capitalize non-GAAP earnings.
Al White has focused on product launches, reorganization savings, free cash flow, share repurchases, debt reduction, and portfolio review. The key question is whether management can turn a Q2 beat into clean cash generation after recall settlements.
Vision correction has durable demand from myopia, aging, premium contact lens upgrades, and eye-care access. Fertility and surgical markets have long-term demographic demand, but they are more sensitive to regulation, reputation, affordability, and procedure volumes.
At $72.61, COO is inexpensive on forward non-GAAP EPS but expensive on TTM GAAP EPS. Margin of safety improves if free cash flow proves durable, recall costs are contained, and the stock holds below normalized value until operating evidence catches up.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| COO quote reference | $72.61 close on July 6, 2026, with a $72.69 July 7 pre-market reference | StockAnalysis COO overview and statistics | July 8, 2026 |
| Market capitalization verification | $14.16 billion reported and $14.16 billion calculated from $72.61 x 195.03 million shares | Pineify financial_rigor.py and StockAnalysis COO statistics | July 8, 2026 |
| Shares outstanding | 195.03 million shares outstanding from StockAnalysis; SEC Q2 filing listed 194.9 million outstanding at April 30, 2026 | StockAnalysis COO statistics and SEC 10-Q | July 8, 2026 |
| FY2025 revenue | $4.092 billion revenue, cross-checked against StockAnalysis and Macrotrends search data | CooperCompanies FY2025 results release | July 8, 2026 |
| FY2025 net income | $374.9 million net income, cross-checked against StockAnalysis FY2025 income statement | StockAnalysis COO financials | July 8, 2026 |
| Q2 2026 results | $1.082 billion revenue, up 8%; non-GAAP EPS $1.21; GAAP EPS $(0.40) after a litigation-related charge | CooperCompanies Q2 2026 results release | July 8, 2026 |
| Segment revenue | Q2 2026 CooperVision revenue $723.5 million and CooperSurgical revenue $358.0 million, both up 8% reported | CooperCompanies Q2 2026 results release | July 8, 2026 |
| Cash, debt, and net debt | $138.8 million cash, $2.46 billion total debt, and about $2.32 billion net debt at April 30, 2026 | SEC Q2 2026 10-Q and StockAnalysis balance sheet | July 8, 2026 |
| TTM valuation inputs | TTM EPS $1.18, book value per share $42.27, FCF per share $2.92, FCF yield 4.02%, and no listed dividend | StockAnalysis COO statistics | July 8, 2026 |
| Technical data | 50-day moving average $64.39, 200-day moving average $72.82, RSI 66.97, and 20-day average volume 3.78 million shares | StockAnalysis COO statistics | July 8, 2026 |
| FY2026 guidance | Fiscal 2026 revenue guidance $4.285 billion to $4.321 billion and non-GAAP EPS guidance $4.58 to $4.66 | CooperCompanies Q2 2026 results release | July 8, 2026 |
This COO AI stock analysis is an informational research tool only. It is not investment advice, a recommendation to buy or sell CooperCompanies stock, or a guarantee of future returns. Forecast scenarios are based on available data as of July 8, 2026, can be wrong, and should be updated when new earnings, litigation, CooperSurgical strategic review, balance-sheet, margin, regulatory, or technical information changes.
